HAZ Stock Chart & Stats
€91.50
€1.50(2.24%)
At close: 4:00 PM EDT
€91.50
€1.50(2.24%)
Day’s Range― - ―
52-Week Range€40.40 - €94.50
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€4.25B
Enterprise Value€4.48K
Total Cash (Recent Filing)€223.38M
Total Debt (Recent Filing)€1.17B
Price to Earnings (P/E)51.1
Beta-0.07
Next Earnings
Nov 05, 2026EPS Estimate
1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding45,497,050
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€99.12Price Target Upside8.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.61
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelHaemonetics benefits from an installed-base model in which adopted collection and hospital systems drive repeat consumables, service and software revenue. This creates customer stickiness, improves revenue visibility and supports durable cash generation.
CSL Plasma ExpansionThe non-exclusive CSL agreement could expand Haemonetics’ plasma equipment footprint and create additional recurring disposable demand. Although timing and scope are undecided, the relationship supports longer-term penetration in a strategically important market.
Growth And Cash GenerationRaised fiscal guidance, broad-based platform growth and strong operating cash flow indicate healthy demand and effective cash conversion. Management’s ability to generate free cash flow while funding operations provides resources for debt reduction and ongoing product investment.
Bears Say
Elevated LeverageHigher leverage reduces financial flexibility compared with prior years and increases sensitivity to weaker earnings, interest costs or slower customer demand. Deleveraging is underway, but debt remains a meaningful constraint on resilience and capital allocation.
Margin And Cost PressureMargin compression alongside higher personnel, acquisition and freight costs could limit operating leverage if inflationary pressures persist. Sustaining profitability will require successful cost control and favorable mix, particularly as external costs remain difficult to predict.
Uneven Segment ExecutionWeakness in non-plasma Apheresis and parts of IVT shows that growth is not uniform across the portfolio. Continued softness could make results more dependent on plasma and vascular-closure momentum, increasing execution and product-mix risk.
Haemonetics News
HAZ FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was €40.40 and its highest was €94.50 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is €4.25B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 05, 2026 which is in 35 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 06, 2026. The company reported €1.006 earnings per share for the quarter, beating the consensus estimate of €0.951 by €0.056.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.14.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 45,497,050 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of €1.006 in its last earnings report, beating expectations of €0.951. Following the earnings report the stock price went down -2.74%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in DE:HAZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€99.12 (8.33% Upside)
€99.12 (8.33% Upside)
Blogger Sentiment
Bullish
DE:HAZ Sentiment 80%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Haemonetics Corp.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAZ Company Deck
HAZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated broad‑based operational momentum: solid revenue and EPS growth, strong performance across core platforms (notably Plasma/Persona PLUS, Hemostasis, and Vascular Closure), upgraded fiscal guidance, and exceptional cash generation and debt paydown activity. Offsetting items include near‑term margin compression from prior‑year software recognition and sequential MedSurg revenue timing, higher operating costs, some OEM/ensoETM weakness in IVT, and continued external inflation/FX/headwind risks. Management emphasized disciplined, conservative guidance and prioritized deleveraging while keeping optionality for share repurchases and organic investment.View all DE:HAZ earnings summariesHAZ Stock 12 Month Forecast
Average Price Target
€99.12
▲(8.33% Upside)